X
FDA panel backs J&J’s potential depression blockbuster
https://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
safety
FDA rejects Allergan’s fibroids drug, citing liver safety concerns
European regulators have already restricted use
GSK’s blockbuster HIV drug linked with birth defects
Regulators issue warning after preliminary study findings
FDA probes Parkinson’s drug safety, Acadia’s shares collapse
FDA under pressure to act following press reports
Acadia shares hit by media doubts over Parkinson’s drug
CNN report raises safety concerns
Cut use of antibiotics in nursing homes, pharmacists say
Pharmacists could train staff to cut prescriptions
